Look back at pharma news in the week to August 30
By Barbara Obstoj-Cardwell. Editor
Deal-making featured prominently in the news last week, first with Amgen reaching agreement to acquire the psoriasis drug Otezla from Celgene for around $13 billion. Also, GlaxoSmithKline was seen to have done a good deal with Ionis Pharma in taking up its option on a hepatitis B program, and takeover target Celgene is still on the buying path, the latest being with Germany’s Immatics Biotechnologies on cell therapies targeting cancer. On the research front, The Medicines Company’s Phase III positivetrial results with inclisiran for LDL-cholesterol is seen likely to impact other PCSK9 inhibitors. Additionally, in the ongoing PCSK9 patent battle, Sanofi and Regeneron scored a victory over Amgen.
Amgen does its deal, secures Otezla to bolster near-term outlook
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze